Centerpulse/Sulzer Medica seeks extension
This article was originally published in Clinica
Sulzer Medica, now renamed Centerpulse, is confident it can substantially reduce the opt-out rate concerning its US settlement agreement and, together with the class plaintiffs, has asked for an extension for the final decision until May 31.
You may also be interested in...
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.